Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Maidit:
I can't say that I heard anything from Tim that was not already in the public knowledge. Can you enlighten us on the matters that Tim mentioned that were not known already to investors?
Dallo;
I agree with you and continue to believe that in its recent RNS announcements (which have been quite numerous) there is reason to believ that both IMM and Avion are serious collaborators and do intend to start the Lupuzor trial as soon as they are satisfied that they have the best Contract Research Organisation to conduct it. I am surprised it has taken so long but the last thing we want to see is a failed trial caused by mistakes in carrying it out.
I cannot believe that IMM would appoint as a director a senior pharma figure whose credentials were set out in its RNS of the 11th August. IMM must be paying him (Dr Laurence Reilly) a substantial salary package. Would they do that if they were not serious in doing deals for the licencing of CIDP and the ROW rights to Lupuzor?
I have invested in IMM for a decade believing that their peptide R and D, including the discovery of Lupuzor, would lead eventually to great advances in immunotherapies and considerable financial success. Despite all the setbacks I still hold to that belief. But it's taking much longer than I imagined, mainly because the first Phase 3 trial of Lupuzor failed. That fate must not be repeated. An extra month of two choosing the best CRO may save years in future.
LLoL:
For me it's always the SP that is important although I note the Bid and Ask prices too. But surely it's only sensible to concentrate on the strike price between these two which I see as representing the floor and ceiling of the price range.
However, in today's case, since there is only one deal and it is at a SP of 2.14p, very little can be read into it.
Maidit308.
"who knows what tomorrow will bring?"
The start of the Lupuzor Phase 2//3 Trial, I hope.
Wildbunch:
There is no point in me phoning Tim. I might/might not learn something that will reassure me. But what is needed is an update for shareholders on the preparations for the Adaptive Phase 2/3 Trial for Lupuzor.. I know this is the No1 concern for shareholders, not just for me.
Oscar:
Thank you for explaining the rationale behind the decision to extend the Share Warrants in Incanthera.
What I would really like an explanation of is the delay in announcing the commencement date for the Phase 2/3 Trial of Lupuzor.
I have heard that the delay arises from the need to conduct due diligence on the various CROs (contract research organisations) which have expressed an interest in carrying out this trial. But even allowing for the importance of ensuring that the chosen CRO has the skill set in its employees to carry out the Trial expertly, it is beginning to stretch credibility that it has taken this long to choose a suitable CRO.
In his last Proactive interview, Tim McC. stated that IMM and Avion had anticipated the go-ahead from the FDA for Avion's proposals for the Trial and were ahead in planning the practicalities including contact with CROs. So far there has been precious little to show for it.
Can you clarify these matters? I am sure there are many like me who are wondering what on earth is going on.
Thanks, Maidit. Like you, I've held IMM shares for several years so I know how difficult/impossible it is to predict this stock's price movements.
But I still can't follow the logic of today's Buy/Sell prices nor the tactic of a shareholder who for the past few days has been buying small tranches of 500 shares costing around £12. I guess it is part of a tactic for changing the market price before he buys big time, but it still makes me scratch my head.
I just wish to God that we had some news about the commencement of the Phase 2/3 Lupuzor trial and/or the CIDP and ROW Lupuzor collaborations. We should then see the SP move to solid double digit numbers.
Can anyone explain what is going on when buyers are paying a lower price for their shares than sellers are receiving for theirs?
MaverickD;
Is the !.7 million a Buy or a Sell in your opinion?
Lambo -
It's very kind of you to offer your financial advice for free to the Board of IMM. I'm sure they appreciate it even tho' you obviously feel they need to be reminded by you at least once a week.
Loadsof ...
I don't agree with you.
As soon as there is an announcement that a pharma has signed a deal to finance the next CIDP trial and to pay IMM a substantial downpayment, likewise with the Lupuzor ROW trial with an upfront payment, then the price will rise substantially. That should be 2 or 3 years ahead the results of the new adaptive Lupuzor trial.
Loadsof.../Maverick
The truth is likely to lie between the two of you. I doubt if news is imminent in the sense of this week or next. Nor do I believe it is years away. I expect that we'll receive news of the start of the Adaptive 2/3 trial for Lupuzor and the appointment of a Contract Research Organisation to carry it out before the end of August.
And I expect that before the end of this half year, but possibly not until November/December, the announcement of a deal with another pharma company to finance the next trial stage for CIDP. And with the same, or a different, pharma company for ROW Lupuzor - but that might take longer and depend on the progress of the adaptive trial about to start.
The most interesting of Oscar's posts this month are dated 3rd and 6th July and both relate to Tim's Proactive interview on the 28th June.
Loads:
There are many of us, like you, facing huge losses, if the company were to go under or be taken over at the present SP. But its clear from Oscar22's posts that this is very unlikely to happen. There are just too many of the senior management/directors/founders who hold large bundles of shares, to let this happen if at all possible.
As to Tim McC and his happy-clappy interviews in past years upon which little confidence could be put, I detect a change in the past year. First, information via RNS notices and Proactive interviews featuring Tim, have been more frequent. Second, they contain more detailed information than in the past about we can expect by way of progress in obtaining FDA approvals and in relation to negotiations with other pharmas for the financing of ROW Lupuzor and for North America and ROW CIDP trials.
Moreover, we have been getting on this board clarifications and analysis by a contributor calling himself/herself Oscar22. It is obvious that whoever this person is, they have much more information than the rest of us about what is really going on within IMM.
For proof, read Oscar's post about Tim's latest Proactive interview. It summarises it into about 9 different headings which actually contain more information than Tim supplied in his interview. Obviously, he didn't have time, or her forgot to mention them all! If you doubt me, listen again to the interview and compare it with Oscar's summary (dated I think, 5th July).
So thanks Tim and thanks Oscar22. I'm encouraged to hold my shares, optimist that I am! And cheer up, Loads!
Lambo:
You are a needle stuck on the same groove of an old record.
As Oscar wrote in his summary of Tim's Proactive interview summary last week, and reiterated yesterday, Tim is convinced that IMM's finances are "robust" and sufficient until 2024. So just use your eyes and read what has been stated on this bb by Oscar who obviously has an inside track as to what is going on in IMM.
I think we are now in a much better place than in previous years when Tim's claims of ROW Lupuzor deals being under discussion had to be taken with a pinch of salt. Now, Tim is actually sticking his neck out and indicating that one or two deals are expected to be signed before the end of this year, one for Lupuzor and one or two (North America and ROW) for CIDP.
So please give up rabbiting on about a 2p share placement. It's not going to happen if Tim and his board have anything to do with it.
Loadsof.....
IMM has no intention or wish to sell out to Avion and as far as one can assess the present actions of Avion and IMM, the former has no intention or desire to buy IMM.
The summary of Tim's Proactive interview supplied last week by Oscar, makes that very point. Tim believes that IMM is on the cusp of major development through agreements with other pharmas for the ROW rights to Lupuzor, and to North American and ROW rights to CIDP. These agreements will involve upfront payments to IMM, says Tim, that will leave it with plentiful cash for its own remaining pipeline and provide uplift to its SP. He made it clear that he wants to change the background of an ultra-low SP as soon as possible.
There are plenty of examples in history of such dramatic changes of fortune, so don't denigrate IMM's efforts.
Avion:
Thanks for your summary of the CEO's interview last week. It is all very positive but I'm left with some questions.
1. What is the timetable for completion of the Phase 2/3 trial?
2. Until there are clear signs that either the Lupuzor or the CIDP trials are completed AND successful, what upward impetus to the SP will take place?
3. Are there any other pharma products in the IMM pipeline which will be ready for the market before Lupuzor and/or CIDP such as BioAMB which have gone off the radar for a while?
As things stand, the market is not yet impressed with IMM's outlook. Let's hope that changes soon.
Apologies WILDBUNCH for misspelling your name. And thanks for explaining your nom de plume.
Wildbush
In my point about CIDP, I meant to write "how confident Tim was of finding a partner to finance the CIDP trials". And that is why I can't understand why you replied to my question on this that he referred only to Lupuzor not CIDP when discussing the next stage of trials.
Wildbush:
Thanks for your clarifications, but I am still puzzled.
From the previous interviews on Proactive, Tim made it clear how confident of finding a partner to finance the CIDP trials.
As far as Phase 2 is concerned, which you say is for Lupuzor, since Avion is already committed to financing Lupuzor in the USA, I presume that you mean the Lupuzor trial in the ROW.? Would it not also be a Phase 2/3 trial similar to the one agreed with the FDA?
Forgive me for all these questions. I am an ignoramus compared to Nolupus as far as IMM is concerned.